Anisodamine

Anisodamine

SCHEMBL29353530

CN1[C@H]2C[C@H](OC(=O)[C@H](CO)c3ccccc3)C[C@@H]1[C@@H](O)C2

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 4/20 0.72
CHRM2 P08172 3/20 0.72
CHRM5 P08912 3/20 0.72
CHRM3 P20309 3/20 0.72
CHRM4 P08173 3/20 0.72
KMT2A Q03164 3/20 0.72
LMNA P02545 3/20 0.72
HTR2C P28335 2/20 0.72
NFKB1 P19838 2/20 0.72
MEN1 O00255 2/20 0.72
BLM P54132 2/20 0.72
KDM4E B2RXH2 1/20 0.72
POLB P06746 1/20 0.72
ADRA2C P18825 1/20 0.72
ADRA1A P35348 1/20 0.72
HRH1 P35367 1/20 0.72
SLC22A1 O15245 1/20 0.72
ADRA1D P25100 1/20 0.72
TSHR P16473 2/20 0.68
CYP1A2 P05177 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Anisodamine SCHEMBL30317064 1.00 CHRM1 (0.72) CHRM1CHRM2CHRM5CHRM3CHRM4
Anisodamine SCHEMBL27981908 1.00 CHRM1 (0.72) CHRM1CHRM2CHRM5CHRM3CHRM4
Anisodamine SCHEMBL30679509 1.00 CHRM1 (0.72) CHRM1CHRM2CHRM5CHRM3CHRM4
Anisodamine SCHEMBL31098813 1.00 CHRM1 (0.72) CHRM1CHRM2CHRM5CHRM3CHRM4
Anisodamine SCHEMBL28725258 1.00 CHRM1 (0.72) CHRM1CHRM2CHRM5CHRM3CHRM4
Anisodamine SCHEMBL620576 1.00 CHRM1 (0.72) CHRM1CHRM2CHRM5CHRM3CHRM4
Anisodamine SCHEMBL30679510 1.00 CHRM1 (0.72) CHRM1CHRM2CHRM5CHRM3CHRM4
SCHEMBL16167837 0.84 CHRM1 (0.76) CHRM1CHRM2CHRM5CHRM3CHRM4
Atropine SCHEMBL8854381 0.84 CHRM1 (1.00) CHRM1CHRM2CHRM5CHRM3CHRM4
Atropine SCHEMBL41317 0.84 CHRM1 (1.00) CHRM1CHRM2CHRM5CHRM3CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12616688-B2 Cell glycocalyx protection effect of anisodamine CHENGDU FIRST PHARMACEDTICAL CO., LTD (CN) 2026-05-05 US claimed
CN-120118309-A Preparation method of crosslinked conductive polymer/Graphene Oxide (GO) composite material, and product and application thereof 上海纳米技术及应用国家工程研究中心有限公司 2025-06-10 CN claimed
CN-118007318-A Solar-driven interface water evaporation and photocatalytic dye degradation dual-functional composite fiber membrane and preparation method and application thereof 成都大学 2024-05-10 CN claimed
CN-117740902-A Cuprous oxide-based ternary composite sensing electrode and preparation method and application thereof 南京工业大学 2024-03-22 CN claimed
EP-4076733-B1 PEROVSKITE SOLAR CELL PROVIDED WITH AN ADSORBENT MATERIAL FOR ADSORBING TOXIC MATERIALS ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) 2024-02-07 EP claimed
US-20230321072-A1 CELL GLYCOCALYX PROTECTION EFFECT OF ANISODAMINE CHENGDU FIRST PHARMACEDTICAL CO., LTD (CN) 2023-10-12 US claimed
US-20230088203-A1 PEROVSKITE SOLAR CELL PROVIDED WITH AN ADSORBENT MATERIAL FOR ADSORBING TOXIC MATERIALS ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2023-03-23 US claimed
CN-115427142-A Perovskite solar cell provided with adsorbing material for adsorbing toxic substances 洛桑联邦理工学院(EPFL) 2022-12-02 CN claimed
EP-4076733-A1 PEROVSKITE SOLAR CELL PROVIDED WITH AN ADSORBENT MATERIAL FOR ADSORBING TOXIC MATERIALS Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO (CH) 2022-10-26 EP claimed
US-12616688-B2 Cell glycocalyx protection effect of anisodamine CHENGDU FIRST PHARMACEDTICAL CO., LTD (CN) 2026-05-05 US disclosed
CN-121263029-A Anti-solvent trans-perovskite battery based on carbon disulfide mixed anisole and preparation method thereof 成都理工大学 2026-01-02 CN disclosed
EP-4594520-A2 COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS Sixfold Bioscience Ltd. (GB) 2025-08-06 EP disclosed
CN-114875107-B POLR2A as biomarker for treating tumor 中南大学 2025-05-27 CN disclosed
CN-120042065-A Polyamide fiber with antibacterial and deodorizing functions and preparation method thereof 福建省力恒锦纶实业有限公司 2025-05-27 CN disclosed
CN-110776654-B Aramid nanofiber/polyvinyl alcohol/polyaniline composite hydrogel and preparation method and application thereof 南京理工大学 2022-06-28 CN disclosed
CN-111099588-B Controllable preparation method of biomass gel-based hierarchical pore ordered three-dimensional network structure carbon material 河南师范大学 2022-06-24 CN disclosed
CN-110894343-B MoO (MoO)3@ PEDOT composite material and preparation and application thereof 中国科学院理化技术研究所 2022-06-21 CN disclosed
CN-114628166-A Preparation method of asymmetric fibrous flexible supercapacitor 闽都创新实验室 2022-06-14 CN disclosed
CN-114275767-A Transition metal nitride/two-dimensional nitrogen-doped carbon composite material and preparation method thereof 华中科技大学 2022-04-05 CN disclosed
CN-113968853-A Hapten and artificial antigen of atropine alkaloid, and preparation method and application thereof 中国农业大学 2022-01-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12616688-B2 Cell glycocalyx protection effect of anisodamine CD14, ICAM1, VCAM1 CHRM1 1006/4885CHRM2 2061/4885CHRM5 1919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.